Blueprint Medicines Co. (NASDAQ:BPMC) Receives $70.59 Consensus Target Price from Brokerages

Shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) have earned a consensus rating of “Hold” from the twenty brokerages that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, five have issued a buy recommendation and one has […]

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Blackrock ,United Kingdom General ,Michael Landsittel ,Brian Druker ,Chris Varma ,Kate Haviland ,Nicholasb Lydon ,Marshall Wace ,Blackrock Inc ,Blueprint Medicines Co ,Needham Company ,Securities Exchange Commission ,Pricet Rowe Associates Inc ,Morgan Stanley ,Barclays ,Blueprint Medicines Corp ,Norges Bank ,Nasdaq ,Blueprint Medicines Company Profile ,Blueprint Medicines ,Get Rating ,Marketbeat Ratings ,Exchange Commission ,Street Corp ,Alexis Borisy ,Blueprint Medicines Daily ,Nasdaq Bpmc ,Bpmc ,Medical ,Ratings ,Consensus ,